Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: rupers who wrote (576)	2/1/2001 6:48:43 PM
From: rupers	Respond to of 2402

siliconinvestor.com Rupers portfolio for the stock-picking challenge.

To: rupers who wrote (576)	2/6/2001 9:13:41 PM
From: Oak Tree	Read Replies (1) \| Respond to of 2402

NABI Took a dive. Think this is long stock not a short. Earnings come out the end of the month. Nabi (NABI: news, msgs) retreated more than 14 percent after the Boca Raton, Fla., biopharmaceutical firm reported on the progress of clinical trials of its StaphVAX vaccine. The company said it's moving forward with stated plans to conduct a boosting study of StaphVAX in patients with end-stage renal disease and that it's making progress with the scale-up of manufacturing operations for commercial production of the vaccine. However, investors appear to have been spooked by news that Nabi is making plans for a second phase-II trial of StaphVAX based on input from the Food and Drug Administration. The company plans to appeal the agency's decision about the need for a second trial and request a meeting with the FDA's vaccines and related biological products advisory committee. Shares fell 78 cents to close at $4.69.